{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-036164","form_type":"8-K","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2026-11-10T21:08:52+00:00","discovered_at":"2026-11-10T21:10:00.232225+00:00","generated_at":"2026-11-10T21:10:17.772925+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Moleculin: Annamycin plus PD-1 blockade extends survival in pancreatic cancer preclinical models","bullets":["In an immunocompetent KPC mouse model of advanced pancreatic ductal adenocarcinoma, liposomal Annamycin (L-ANN) plus PD-1 blockade increased survival vs either agent alone; reconfirmed independently.","Annamycin reached substantially higher and more sustained pancreatic tissue exposure than doxorubicin at the same dose, with increased CD8+ cytotoxic and CD4+ helper T-cell infiltration.","Depleting CD8+ T cells shortened survival in treated mice, showing the immune system contributes to Annamycin's antitumor activity rather than being a bystander.","Data presented Nov 10, 2026 by Waldemar Priebe, PhD of MD Anderson at the Marie Sklodowska-Curie Symposium in Tampa, building on AACR April and September 2026 results.","CEO Walter Klemp said the priority remains the MIRACLE AML trial with a Q1 2027 data readout; Moleculin plans to sponsor an investigator-initiated pancreatic cancer trial in 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-036164","json":"https://secwatch.observer/filing/0001437749-26-036164.json","markdown":"https://secwatch.observer/filing/0001437749-26-036164.md","text":"https://secwatch.observer/filing/0001437749-26-036164.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926036164/0001437749-26-036164-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926036164/mbrx20261109_8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-11-10T21:10:17.772925+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}